Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of Recombinant human thrombopoietin in patients with severe aplastic
anemia and very severe aplastic anemia, a randomized, double-blind, placebo-controlled, II
phase, multi-center clinical research.